Capricor’s lead candidate, CAP-1002, is a cardiac cell therapy that is currently in clinical development for the treatment of heart disease associated with Duchenne muscular dystrophy (DMD) as well as adult cardiology indications. CAP-1002 is an allogeneic product, meaning that it is manufactured from donor heart tissue and then stored until needed for use. Patients receive CAP-1002 by infusion into one or more coronary arteries during a standard catheterization procedure. CAP-1002 has been granted orphan drug designation by the FDA for the treatment of DMD.
Capricor plans to expand its clinical efforts for CAP-1002 and is designing a clinical trial to evaluate the potential ability of CAP-1002 to benefit skeletal muscle function in boys and young men with DMD. In this planned study, which is expected to begin in 2017 subject to regulatory approval, the medication will be given by systemic intra-vascular administration, a convenient delivery method.
Capricor and Janssen Biotech, Inc., pursuant to their Collaboration Agreement , are working on developing a commercial manufacturing process for CAP-1002.
View a list of publications relating to CAP-1002.